FDA rejects Regenxbio’s Hunter syndrome gene therapynews2026-02-09T21:15:23+00:00February 9th, 2026|Endpoints News|
With scant data, RFK Jr. credits Trump for higher European drug pricesnews2026-02-09T20:44:29+00:00February 9th, 2026|Endpoints News|
QuantX raises $85M Series B from Lilly, Sanofi Venturesnews2026-02-09T18:26:47+00:00February 9th, 2026|Endpoints News|
Despite FDA’s crackdown, pharma is still spending millions on adsnews2026-02-09T16:06:06+00:00February 9th, 2026|Endpoints News|
Lilly joins in vivo CAR-T sprint with $2.4B Orna acquisitionnews2026-02-09T15:25:12+00:00February 9th, 2026|Endpoints News|
Galux raises $29M Series B; CSL teams up with Memonews2026-02-09T15:10:23+00:00February 9th, 2026|Endpoints News|
#ACTRIMS26: Roche’s MS drug fenebrutinib beats Ocrevus, cutting risk of disability progression by 12%news2026-02-09T14:15:12+00:00February 9th, 2026|Endpoints News|
Takeda, Iambic sign multiyear R&D deal for AI drug discoverynews2026-02-09T13:00:13+00:00February 9th, 2026|Endpoints News|
Novo Nordisk sues Hims over Wegovy patent infringement, considers seeking ‘hundreds of millions’ in damagesnews2026-02-09T12:04:55+00:00February 9th, 2026|Endpoints News|
Lilly returns to Innovent to partner on cancer and immune diseasesnews2026-02-09T09:28:38+00:00February 9th, 2026|Endpoints News|
